The introduction of anti-vascular endothelial growth factor (anti-VEGF) has significantly reduced visual loss due to
neovascular age-related macular degeneration (n-AMD). However there are significant inter-individual differences
in response to an anti-VEGF agent due to a variety of factors including patient’s age, lesion characteristics,
lesion duration, baseline visual acuity (VA) and the presence of particular genotype risk alleles.
Modern Medicine – March 2018